I've created a WhatsApp group to share stocks with huge upside potential. Many participants have increased their initial $5,000 investment to $90,000. 🥳 My WhatsApp link: https://t.co/9fGCtsJCpl Reply with "9" on WhatsApp to join for free. 🚀

$RKLB The company has over $754 million in cash and boasts a 36% annual revenue growth rate. With its earnings report approaching, $RKLB's stock price could surge by 20%/30% or more. By December, revenue will exceed $80.

$TSLA has begun an exciting upward trend and is poised to reach a new all-time high and break the $500 mark in the coming days… $TSLA and $PLTR are in the same upward phase and are expected to gain over 200%/300% within a few months. It is projected to surpass $600 soon.

$IOVA Strong Resurgence in Cell Therapy Q2 Revenue Exceeds $60 Million, Up 93% Year-over-Year Iovance Biotherapeutics' performance has surged as TIL therapy gains momentum Significant progress has been made in melanoma treatment with expansion into new cancer indications

Featured: $NUWE Price: $3.05 The recent trading days have seen a clear series of large bearish candlesticks, a typical sign of panic selling. Selling pressure is extremely high in the short term, and technically the market is in an "oversold" state.

Featured: $UPC Price: $4.82 Recent trading volume has increased significantly compared to before, indicating increased market activity. However, the price has fallen after the increase in volume, suggesting that short-term funds are taking profits.

Featured: $VTYX 🚀 Positive Phase 2 data for the NLRP3 inhibitor VTX3232 sparked significant market volatility. The market is waking up to potential blockbuster stocks in the inflammation and cardiometabolic sectors. Focus on $VTYX—Biotech Momentum is Strong! #VTYX #Biotech

Featured: $LUNG Strong rebound after solid Q2 growth – revenue up 15% year-over-year Speculation on lung disease treatment technology (Zephyr Valve) 52-week range: $1.47 - $9.37 Watch $LUNG – Strong momentum!

Featured: $LUNG Strong rebound after solid Q2 growth – revenue up 15% year-over-year Speculation on lung disease treatment technology (Zephyr Valve) 52-week range: $1.47 - $9.37 Watch $LUNG – Strong momentum!

Featured: $WBUY Price: $2.52 The stock price has entered a period of sideways trading after a sharp drop, and short-term traders may be waiting for a directional breakout. The lack of a clear reversal pattern suggests the rebound is not yet strong enough.

Featured: $LICN Price: $3.85 Trading volume increased significantly during the sharp drop, indicating a concentrated capital outflow. During the rebound phase, trading volume significantly weakened, and the rebound strength was limited.

Featured: $TAOP Price: $2.51 The rebound after the previous sharp drop is close to the initial stage of a "V-shaped reversal." However, it has not yet effectively broken through the previous high, so the reversal is not yet confirmed and still needs confirmation.

Featured: $JFBR Price: $3.30 The long lower shadows of the recent candlesticks suggest buying activity at lower levels, potentially weakening bearish momentum. If the price maintains a steady rise above 3.40, the technical outlook suggests a short-term rebound.

$RXRX Target Price: $7.15, $8.07 Recursion faces resistance at the July high of $7.15. A close above this level is needed to reach the next target of $8.07. Current support is at $6.11.

$SMCI Target Price: $66.44 The SMCI appears to have found support in the $52.00 area. If this support level holds, a descending wedge pattern could form, which typically signals an upside breakout. The next target is $66.44.

Featured: $DRMA Price: $4.18 Support: Currently, $4.00 is a short-term support level. Resistance: Short-term resistance is around $4.30, followed by $4.70. If the price breaks above $4.30 on strong volume, it could test $4.70 or even higher.

Featured: $WBUY Price: $2.49 Caution is advised in short-term trading. Wait for volume to recover and for a breakout above key resistance levels before entering the market. For medium- to long-term trading, observe for signs of a stabilization and improving fundamentals.

Featured: $UPC Price: $4.80 Technically weak, with no clear reversal signals. Confirmation of a trend reversal requires significant volume growth and a breakout above key resistance levels. Otherwise, continued downward volatility is likely.

Featured: $DRMA Price: $4.11 The short- to medium-term trend remains weak, with the rebound lacking sustainability and no clear bottoming pattern forming during the decline. If the stock price falls below the $4.00 support level, it could potentially head towards $3.80.

Featured: $PBM Price: $3.45 The short-term pattern resembles a high-level oscillation pattern of a sharp rise followed by a decline, and is currently in a sideways consolidation phase. There is no clear upward trend, but rather a more pronounced consolidation after a peak.